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Abstract
Introduction: The eMERGE (electronic MEdical Records and GEnomics) Network is an NHGRI-supported consortium
of five institutions to explore the utility of DNA repositories coupled to Electronic Medical Record (EMR) systems for
advancing discovery in genome science. eMERGE also includes a special emphasis on the ethical, legal and social
issues related to these endeavors.
Organization: The five sites are supported by an Administrative Coordinating Center. Setting of network goals is
initiated by working groups: (1) Genomics, (2) Informatics, and (3) Consent & Community Consultation, which also
includes active participation by investigators outside the eMERGE funded sites, and (4) Return of Results Oversight
Committee. The Steering Committee, comprised of site PIs and representatives and NHGRI staff, meet three times
per year, once per year with the External Scientific Panel.
Current progress: The primary site-specific phenotypes for which samples have undergone genome-wide
association study (GWAS) genotyping are cataract and HDL, dementia, electrocardiographic QRS duration,
peripheral arterial disease, and type 2 diabetes. A GWAS is also being undertaken for resistant hypertension in
≈2,000 additional samples identified across the network sites, to be added to data available for samples already
genotyped. Funded by ARRA supplements, secondary phenotypes have been added at all sites to leverage the
genotyping data, and hypothyroidism is being analyzed as a cross-network phenotype. Results are being posted in
dbGaP. Other key eMERGE activities include evaluation of the issues associated with cross-site deployment of
common algorithms to identify cases and controls in EMRs, data privacy of genomic and clinically-derived data,
developing approaches for large-scale meta-analysis of GWAS data across five sites, and a community consultation
and consent initiative at each site.
Future activities: Plans are underway to expand the network in diversity of populations and incorporation of
GWAS findings into clinical care.
Summary: By combining advanced clinical informatics, genome science, and community consultation, eMERGE
represents a first step in the development of data-driven approaches to incorporate genomic information into
routine healthcare delivery.
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The mapping of the human genome has enabled new
exploration of how genetic variations contribute to
health and disease. To better realize this promise, the
National Human Genome Research Institute (NHGRI)
called on researchers to determine how genetic variants
influence susceptibility towards chronic conditions such
as diabetes, Alzheimer’s disease, and cardiovascular dis-
ease, in order to ultimately improve patient care [1].
This effort has been remarkably successful [2]. The
results of this work form the cornerstone not only for
discovery of new biologic pathways and drug targets,
but also for enabling a vision of “personalized medicine”
in which genomic (and other personal health informa-
tion) is incorporated into the fabric of healthcare. Deli-
vering such advances to the bedside will require
advanced information technology, based on electronic
medical record (EMR) systems. Each of the five sites in
the eMERGE network, formed to address these chal-
lenges, includes a DNA repository linked to an EMR,
and thus the network is acting as a test bed for enabling
such a future vision of healthcare. Further, aggregation
of results across the network could represent an initial
step toward the generation of a large prospective cohort
in which healthcare status linked to biosamples are used
to evaluate the impact of both genes and environment
[3] on important human phenotypes, i.e. a trans-
institutional or ultimately a national biobank. There are
many challenges, however, to the successful execution of
this idea: examples include validation and harmonization
of phenotypes identified using medical records data,
integration of genomic and phenotypic data across mul-
tiple sites for combined GWAS analysis, and adequacy
of informed consent to share GWAS data widely, such
as in the database of genotypes and phenotypes (dbGaP)
[4], managed by the NIH.
The stated goals of the eMERGE Network (http://
www.gwas.net) are to develop and apply approaches for
using U.S. biorepositories linked to EMR systems for
large-scale genomic research by determining: 1) the
completeness and validity of phenotypic and exposure
information derived from EMR; 2) the adequacy of
existing consent for sharing data widely with other
investigators within the network and outside the net-
work through dbGaP; 3) the needs for additional con-
sent and/or consultation with biorepository participants,
investigators and other relevant groups; 4) best practices
for IRB interactions, participant consent, and results
reporting, and for collecting, documenting and sharing
data; 5) representativeness and diversity of biorepository
participants; and 6) associations of genome-wide data
with EMR-defined phenotypes. Each center participating
in the consortium, organized by the NHGRI with addi-
tional funding from the National Institute of General
Medical Sciences, proposed to study the relationship
between genome-wide genetic variation and a common
disease/trait. In addition, the consortium includes a
focus on ethical issues such as privacy, confidentiality,
and interactions with the broader community.
Network Structure, Aims and Progress
All sites proposed a specific disease-related GWAS with
specific aims related to validation of electronic pheno-
typing and community consultation. At each site, identi-
fication of ~3,000 phenotype appropriate subjects was to
be followed by a GWAS in that set, as well as a 6
th
GWAS (~2,000 samples) accrued across the network.
To identify subjects for study, electronic algorithms are
developed, validated, and modified if necessary until
positive predictive values of at least 95% are achieved
where possible. All sites committed to making their
electronic algorithms and NLP tools widely available
and to sharing GWAS data for validated cases and con-
trols for the other network site outcomes.
Network Organization
The network was formed in fall 2007, and its organiza-
tional structure is shown in Figure 1. The steering com-
mittee (Principal and other investigators and NHGRI
staff) meets 2-3 times annually. Setting of network goals
is initiated by the working groups: (1) Genomics,
(2) Informatics, (3) Consent & Community Consultation
Working Group, which also includes active participation
by investigators outside the eMERGE funded sites, and
(4) Return of Results Oversight Committee. A five-
member External Scientific Panel (ESP) was formed to
provide independent input to the NHGRI director about
the progress and direction of the Network and meets
annually with the Steering Committee.
Administrative Coordinating Center
The eMERGE Network Administrative Coordinating
Center (ACC), at Vanderbilt University Medical Center,
provides a range of support to the network including
coordination of steering committee meetings, organiza-
tion of and support for working groups, a communica-
tions hub with public and private pages (http://www.
gwas.net), and support for the ESP. In addition to
administrative support, the ACC has assumed responsi-
bilities for coordination of informatics and genomics
efforts across sites. These include: 1) developing meth-
ods to compare the clinical characteristics of popula-
tions with specific disease phenotypes identified across
institutions in the network; 2) providing standardized
quality control for genotypes generated across the net-
work and 3) Data Privacy Consultation service to assist
in quantifying the risk of re-identification of de-
identified data, e.g., by comparison of sets of diagnostic
codes to publicly available Medicare data, health and
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received a supplement to provide standardized QA/QC
for the genotypic data for all sites.
Site-specific Biorepository Descriptions and Aims
There are five sites in eMERGE: Marshfield, Northwes-
tern, Mayo, Group Health Seattle, and Vanderbilt. In
the following sections, the biobank at each institution is
first described, followed by a brief description of the
phenotypes being studied and community consultation
activities. Key features of each biobank are summarized
in Table 1.
Marshfield Clinic Research Foundation
Biobank description The Marshfield Clinic Personalized
Medicine Research Project (PMRP) is a population-based
biobank with approximately 20,000 adult participants
and access to an average of 30 years of medical history
data [5-7]. DNA, plasma, and serum samples are stored,
with written informed consent from participants to allow
sharing of de-identified samples and data. At the time of
enrollment, subjects completeab r i e fq u e s t i o n n a i r ew i t h
demographic and personal behavior data including smok-
ing and alcohol intake, and detailed food frequency
questionnaire.
eMERGE project aims Phenotypes
Marshfield is developing and validating two primary
outcomes: high-density lipoprotein (HDL) and cataract
and quantifying the impact of two environmental factors
(cigarette smoking and statin use) known to influence
each of the primary study outcomes. Age-related catar-
act is the leading cause of blindness globally and low
HDL cholesterol levels are a risk factor for myocardial
infarction, the leading cause of mortality in the US. No
GWAS data are available for cataract and no gene/envir-
onment GWAS data are available for HDL cholesterol
levels. In addition to an epidemiologic association and
shared risk factors, cataract and low HDL cholesterols
levels were selected because of the suspected difficulty
to develop validated electronic algorithms. Cataract was
expected to be the most difficult because Ophthalmol-
ogy was the last Department at the Marshfield Clinic to
use the EMR and because much of the components of
an ophthalmic exam necessary to define phenotype are
not gathered in structured format and would require
more sophisticated electronic tools, including natural
language processing (NLP). In addition to NLP, intelli-
gent character recognition (ICR) is being used to iden-
tify cataract type from the clinical notes.
Another outcome, diabetic retinopathy, was selected
for funding through an ARRA supplement to mine the
Figure 1 Organizational structure of the eMERGE network.
Table 1 Comparison of Biobanks and Phenotypes Across the eMERGE sites
Site Biobank design Biobank size and demographics Phenotypic outcomes
Marshfield Population-based 20,000; 98% Caucasian, mean age
48, range 18-102
Low HDL cholesterol, cataract (n =
3968) Secondary: diabetic
retinopathy
Mayo Clinic PAD cases identified from the Mayo non-invasive vascular
laboratory database; control subjects without PAD
identified from the Cardiovascular Health Clinic
1687 cases (mean age 65) and 1725
controls (mean age 60)
Peripheral arterial disease (PAD) (n
= 3412); Secondary: red blood cell
indices
Northwestern Outpatient clinic and hospital-based Approximately 10,000; 12% African
American, 8% Hispanic; Mean age
50, range 18 - 90+
Primary: type II diabetes (n =
3531); Secondary: lipids and height
Group Health ACT Study Cohort of aged 65 and olderrandomly sampled
from an HMO all known not to be demented at
enrollment and followed for development of dementia,
and Alzheimer’s Disease (source of cases and controls)
ADPR: Alzheimer’s disease cases from a model incidence
case registry (source of cases)
Approximately 4000 persons over
age 65 from ACT Study
Alzheimer Disease (n = 3390),
carotid artery stenosis; Secondary:
statin adverse events
Vanderbilt Use of discarded blood/non-human subjects linked to
electronic medical records
Approximately 75,000; 70%
Caucasian, 10% African American;
mean age 53, range 18-100
Electrocardiographic QRS duration
(n = 3192); Secondary: PheWAS
McCarty et al. BMC Medical Genomics 2011, 4:13
http://www.biomedcentral.com/1755-8794/4/13
Page 3 of 11phenotypic data available for subjects being genotyped
for the primary outcomes. Diabetic retinopathy was
selected for several reasons. First, this outcome leverages
the primary outcome of diabetes in the eMERGE net-
work, as well as leveraging cases and controls from
other sites to improve statistical power. Second, diabetic
retinopathy is the leading cause of vision impairment in
working aged adults and there have been no GWAS
data published on this outcome.
Community consultation
Quarterly meetings of the PMRP Community Advisory
Group and quarterly newsletters are used to engage and
inform the public about this GWAS and the sharing of
data with the wider research community. The external
Ethics and Security Advisory Board, chaired by Norman
Fost from the University of Wisconsin, was reconvened
in the context of eMERGE to advise on the updates to
the consent form. After revising the existing consent
form document to be more explicit about data sharing
into dbGaP and making other changes to reflect proto-
col changes since the original consent form was written
and approved in 2002, a computer-based consenting
process is being developed and evaluated. Built-in ques-
tions to evaluate knowledge and understanding will
allow investigators to confirm informed consent prior to
enrollment.
Northwestern University
Biobank description The Northwestern University bior-
epository, NUgene (http://www.nugene.org), is a clinic-
and hospital-based biobank with approximately 10,000
adult participants from the patient population at the
Northwestern University Medical Center (NUMC) [8,9].
Participants’ DNA samples are coupled with data from
an enrollment questionnaire and longitudinal data from
the EMR representing actual clinical care events.
NUgene has access to participants’ clinical care data via
a consolidated data warehouse. Participants consent to
distribution and use of their coded DNA samples and
data for a broad range of genetic research conducted by
third-party investigators. Supplementing the EMR data,
participants complete a standardized enrollment ques-
tionnaire that captures self-reported demographics, race
and ethnicity, selected environmental exposure data,
individual health history, and family history of disease.
The NUgene population is representative of five-county
Chicago area (Cook, DuPage, Kane, Lake, McHenry, and
Will counties) based on comparisons of sex, age, race
and ethnicity with census data. NUgene represents a
clinically diverse population, including samples and data
from healthy individuals and patients with common
adult onset conditions.
NUMC has been operating comprehensive, commer-
cial EMR systems for both inpatient and outpatient
populations for over 10 years. Phenotypic data on
NUgene participants is mined through Northwestern’s
Enterprise Data Warehouse (EDW) which consolidates
clinical data from all patients receiving care at NUMC.
Established to enable clinical and translational research,
the EDW currently stores over 2 million patient records.
eMERGE project aims Phenotypes
Northwestern’s primary phenotype for eMERGE
focuses on type 2 diabetes. Multiple GWAS for type 2
diabetes have been completed and susceptibility variants
have been identified [10], providing known targets to
test the hypothesis that EMR-derived phenotypes can be
used as an alternative approach to identify variants asso-
ciated with disease. Northwestern is developing and vali-
dating computational algorithms to identify cases and
controls from NUgene, and other eMERGE populations,
for type 2 diabetes GWAS. Approaches are also being
developed to extract variables for known type 2 diabetes
confounders. The eMERGE type 2 diabetes GWAS
population is comprised of samples from NUgene and
BioVU at Vanderbilt University, and focuses case and
control selection to maximally include participants of
African American ancestry.
Through the Northwestern ARRA supplement, investi-
gators are leveraging available GWAS and EMR data
across the network to study serum lipid levels (total
cholesterol, HDL, LDL, and triglycerides) as continuous
traits, as well as height. To date, published GWAS have
only explained a small amount of the variance among
lipid traits which are known to be influenced to differ-
ent degrees by environmental factors. These factors will
be addressed across the network.
Community Consultation
Since its inception, the NUgene Project has involved
advisors from the NUMC scientific, medical, and ethics
community as well as external advisors consisting of
community members, community engaged researchers
and public health experts. Through eMERGE, the focus
of these consultations is on issues surrounding consent
for GWAS and data sharing with dbGaP and other net-
work investigators. The Northwestern University IRB
has played a pivotal role in providing guidance sur-
rounding consent for GWAS and appropriate means to
inform participants about data sharing. NUgene con-
tinues to engage the community advisory committee on
GWAS and data sharing as well as providing additional
information to participants through a newsletter. North-
western’s eMERGE community engagement research
consists of a 3-phased approach to learning about parti-
cipant and public concerns about data sharing and
obtaining appropriate consent for GWAS [11], engaging
IRBs about data sharing issues, and holding consensus
meetings with professional stakeholders to determine
appropriateness of our consent process for GWAS and
data sharing.
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Biobank description The Mayo biobank is a disease-
specific biobank for peripheral arterial disease (PAD).
PAD patients were identified from individuals referred
to the non-invasive vascular laboratory for lower extre-
mity arterial evaluation. Since 1997, laboratory findings
have been recorded into an electronic database employ-
ing an in-house software package for data archiving and
retrieval; this data becomes part of the Mayo EMR.
Patients referred to the center with suspected PAD
undergo a comprehensive non-invasive evaluation
including the ankle-brachial index (ABI) - the ratio of
blood pressure measured in the upper arms divided by
blood pressure measured at the ankles. Controls subjects
are identified from patients referred to the Cardiovascu-
lar Health Clinic for screening for cardiovascular dis-
ease. A large proportion of these patients has undergone
exercise ECG to rule out coronary artery disease. Data
regarding risk factors for atherosclerosis such as dia-
betes, dyslipidemia, hypertension, and smoking are
ascertained from the EMR.
eMERGE project aims Phenotypes
For the eMERGE project, the Mayo site chose PAD, a
relatively prevalent disease affecting ~8 million adults in
the US including nearly 20% of the elderly (>70 years of
age). PAD is associated with significant mortality and
morbidity [12,13]. However not much is known about
the genetic bases of PAD even though several GWAS
for coronary artery disease have been completed and
multiple susceptibility variants identified. The Mayo
GWAS for PAD will complement current understanding
of the spectrum of genetic variants associated with
atherosclerotic vascular disease. Additional analyses are
attempting to understand how environmental and life-
style measures (e.g., smoking), identified from the Mayo
EMR, modify the observed relationship between geno-
type and the atherosclerotic vascular disease phenotypes
(i.e., gene-environment interaction).
The specific aim of the Mayo supplementary proposal
is to identify genomic loci influencing red blood cell
(RBC) indices using a GWAS approach in cohorts of the
eMERGE network. The RBC indices include RBC count,
hemoglobin level, mean corpuscular volume, mean cor-
puscular hemoglobin, RBC distribution width and ery-
throcyte sedimentation rate. The findings from the
proposed analyses will help to characterize molecular
mechanisms underlying inter-individual variability in
RBC indices, provide novel insights into anemia and
related hematologic diseases, and could eventually con-
tribute to the development of new therapeutic
approaches for such diseases.
Community Consultation
Since genomic data cannot easily or with certainty be
fully de-identified or anonymized, an important aim of
the Mayo eMERGE project is to engage extensively with
research participants and the community regarding best
practices to weigh the future benefits of genomic
research to patients, families, and the society against the
potential risks. The investigators will develop and refine
consenting procedures in collaboration with Mayo’sI R B
on the basis of these findings, through an “Ethics Incu-
bator” developed as part of Mayo’s Clinical and Transla-
tional Science Award (CTSA). A combination of in-
depth patient interviews, consenting “experiments”,a n d
community engagement using Deliberative Democracy
methods are being employed.
Group Health Cooperative, University of Washington and
the Fred Hutchinson Cancer Research Center
Biobank description The Group Health (GH) biobank
for eMERGE is based within an established and growing
cohort of 3,793 patients recruited within GH and
actively followed for Alzheimer’s Disease (AD) and
dementia. Two sub-samples from GH form the specific
population analyzed in this project. The Alzheimer’s
Disease Patient Registry (ADPR) [14] was established in
1986. A related study, Genetic Differences, allowed col-
lection of DNA for persons in the ADPR. The ADPR
was complemented in 1994-1996 and ultimately suc-
ceeded by the prospective Adult Changes in Thought
(ACT) study [15]. Both ADPR and ACT were initiated -
and continue in their 23
rd year - with funding from a
U01 from the National Institute on Aging. ADPR
enrolled 695 dementia cases from GH. ACT enrolled
2,581 dementia-free individuals in 1994-1996, with 811
additional dementia-free individuals from 2000-2002,
and has since 2005 been enrolling dementia-free sub-
jects continuously with identical methods to keep at
least 2000 person-years under observation at all times.
DNA is available on 95% of the cohort. The ACT sub-
sample is well-characterized, with research assessments
every 2 years of risk factors, cognition, blood pressure,
physical performance, over-the-counter medication use,
and other research-quality study data on both pheno-
types and environmental exposures. The ACT sub-sam-
ple is stable; for the original cohort, median enrollment
in GH was 19 years prior to joining the ACT study, and
85% of the cohort has ≥10 years of GH enrollment. This
is a useful cohort for population-based genome-wide
GWA studies and offers the somewhat unique charac-
teristic of very long-term longitudinal data. The cohort
also has noteworthy value as controls for subsequent
GWA analyses of other phenotypes, as it is well-charac-
terized, and many participants have lived to advanced
old age under continuous observation.
eMERGE project aims Phenotypes
Group Health’s primary phenotype of interest is
Alzheimer’s Disease (AD) using dementia cases and
controls within the GH biorepository, based on
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process was used to identify cases in ACT. The Cogni-
tive Abilities Screening Instrument (CASI) [16] is a cog-
nitive test derived from the Mini-Mental State
Examination (MMSE) [17]. The CASI is administered to
all ACT participants every 2 years. CASI scores ≤85
prompt a dementia evaluation; for comparison purposes,
in the Honolulu Asia Aging Study (HAAS) the CASI cut
point is 74. Informant, subject, or staff reports of cogni-
tive difficulties also trigger evaluation. The 2
nd stage
diagnostic examination has two parts: neuropsychologi-
cal testing and a neurological exam by a physician. Med-
ical records are abstracted for standardized labs
(complete blood counts, chemistry panel, B12,t h y r o i d
stimulating hormone) and neuroimaging. If any of these
a r eu n a v a i l a b l ei nt h ep r i o ry e a rt h e ya r eo b t a i n e d .
These data are used to complete standard DSM-IV diag-
nostic criteria for dementia and subtypes, NINCDS-
ADRDA criteria for AD, and 3 sets of criteria for vascu-
lar dementia. The dementia neuropsychological battery
includes tests of clock drawing, verbal fluency, Mattis
Dementia Rating Scale, Boston naming, verbal paired
associations and recall, logical memory and recall, Word
List Memory, Constructional Praxis and recall, Trails A
and B, and Information and Comprehension subtest
items. All clinical data are reviewed at a consensus con-
ference. These procedures have been used continuously
over 23 years since the inception of the ADPR in 1986.
ACT dementia and AD diagnoses have been used in
many papers, including an i n c i d e n c er a t ep a p e r ,a n d
high-impact papers on exercise
18, cholesterol
19, statins
20,
and vitamins
21.
Group Health used its “gold standard” dementia cases
and controls to create and validate an EMR-based
dementia definition. Development of the definition
included examination of a number of ICD-9 codes for
Alzheimer’s disease, number of codes plus an “event”
(neuroimaging, B12, TSH assays), codes by specialty
providers vs. generalists, and fills for dementia drugs.
The best criterion found for all-cause dementia was ≥ 5
ICD-9 codes for Alzheimer’sD i s e a s ea n d / o r≥ 1 fill for
a dementia medication. This EMR definition has a sensi-
tivity of 55% and positive predictive values of 73%. The
EMR definition is being used to identify additional
dementia cases from other participating sites. White
blood cell (WBC) indices are being studied as secondary
phenotypes with ARRA supplement funds.
Community Consultation
The University of Washington and Group Health have
also implemented a consensus process with key stake-
holders to develop recommendations concerning con-
sent, data sharing, and return of research results to
subjects. Stakeholders will include ACT subjects, GH
patients, GH leadership, and ACT investigators. The
consensus process is being informed by targeted focus
group data collection from ACT subjects, GH enrollees
and clinicians. Results and recommendations will be
shared with other network sites and publicized.
Vanderbilt University
Biobank description The Vanderbilt biobank, BioVU,
uses an “opt-out” model, based on the collection of
DNA from discarded blood samples. Details of the sys-
tem, including the methods of sample accrual, deidenti-
fication of patient records, and extensive internal and
external review that the project continues to undergo,
have been published elsewhere [22].
In brief, the approach adopted is based on federal
Office for Human Research Protections (OHRP) guide-
lines (http://www.hhs.gov/ohrp/policy/cdebiol.pdf) stat-
ing that that use in research of discarded samples that
are de-identified and not readily re-identified does not
involve human subjects and so is not subject to the fed-
eral regulations for human subjects research (45 CFR
46, also called the Common Rule).
The Vanderbilt University Medical Center EMR has
been developed as a clinical care and research tool over
the past 15 years and covers all inpatient and outpatient
data entry in the health system, including labs, drug
ordering, and diagnostic imaging [23]. It includes >1.9
million records, and provides a platform for the devel-
opment of tools, such as Natural Language Processing
approaches, to optimally mine structured data and
unstructured (free-form) text in the medical record.
A key component of the BioVU project is the Synthetic
Derivative (SD), a research-optimized copy of the Van-
derbilt EMR from which identifiers have been removed.
BioVU acquires and deidentifies blood samples
obtained in out-patient clinics and scheduled to be dis-
carded by Clinical Pathology. The link between clinical
information in the SD and the DNA sample is retained
by labeling each sample and each entry in the EMR by a
Research Unique Identifier (RUI) generated by the
Secure Hash Algorithm (SHA-512), developed by the
National Security Agency of the United States Federal
Government (http://www.nsa.gov/ia/_files/os/redhat/
rhel5-guide-i731.pdf). SHA-512 is a publicly available
hash function, an algorithm that produces a string of
128 characters that is unique to a particular input; in
other words, it will always generate the same output
(RUI, in this case) given the same input (medical record
number, in this case). Sample handling and de-identifi-
cation procedures underwent extensive pre-launch eva-
luation that has been previously reported [22].
eMERGE project aims Phenotypes
The primary site-specific phenotype that is being ana-
lyzed by GWAS in the Vanderbilt Genome Electronic
Records (VGER) project, the Vanderbilt component of
eMERGE, is duration of QRS complex on the surface
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tion velocity. Natural language processing and other
approaches are being used to identify ECGs designated
as clinically normal in subjects without conditions
thought to affect QRS duration, such as heart disease or
certain drugs. The ECG is one of the most commonly-
ordered tests and provides information on heart disease
and on variation - even within the normal range - of
key indices of cardiac function. Specifically, slow con-
duction enables abnormal heart rhythms, a major public
health problem, so analysis of the duration of the QRS
complex is a first step in identifying new pathways to
arrhythmias.
The availability of genotypes across a large number of
subjects with phenotype-rich records has enabled Van-
derbilt investigators to start to explore the capabilities of
a “Phenome-wide Association Study” (PheWAS) [23].
The BioVU ARRA supplement aims to extend this
approach to other sites in eMERGE.
Community Consultation
The VGER aims related to community consultation are
1) to assess the ethical, scientific, and societal advantages
and disadvantages of the BioVU model, and determine
best practices for oversight, community involvement, and
communication as the resource grows; and 2) to develop
and evaluate formal privacy protection models for data
derived from databanks and EMRs, establishing data
sharing and integration practices.
Retrieved from http://www.mc.vanderbilt.edu/victr/
dcc/projects/acc/index.php/About
Current Status of the Network
Choice of genotyping platform and QA
As of June 2010, all sites had received genotyping data
from DNA samples that had been shipped to NHGRI-
designated central genotyping laboratories at the Broad
Institute and the Center for Inherited Diseases Research at
Johns Hopkins University. The Illumina 660Wquad1a was
selected as the genotyping platform for subjects of Eur-
opean ancestry and other racial/ethnic groups than Afri-
can Americans, while the Illumina 1 M product is being
used for African-American subjects. The distribution of
samples across sites and primary phenotypes is included
in Table 1. The process for quality control (QC) of the
genotyping data is discussed at weekly teleconferences led
by the Administrative Coordinating Center (ACC) with
participants from NHGRI, NCBI, the genotyping centers,
and the Genomics workgroup. The Genomics workgroup
is developing a uniform QC pipeline for the eMERGE net-
work that will be publicly available upon completion.
Sharing of genotype and phenotype data
To compare phenotypes across sites, data sharing agree-
ments have been initiated between the individual
eMERGE sites and the consortium’s ACC and between
all of the individual sites. These allow sharing of
de-identified ICD-9 codes to compare underlying popu-
lation characteristics among the sites, and to share phe-
notypic and genotypic data to allow the combining of
data to increase sample size and allow for replication.
For example, additional dementia cases were provided
by two sites to augment the cases at GHC.
One example of increased statistical power afforded by
the network is presented in Table 2 for one of the sec-
ondary outcomes (diabetic retinopathy) that leverages
genotyping already performed for one of the primary
eMERGE phenotypes.
Another example of cross-site collaboration is in the
QA/QC of all of the GWAS genotype data. The ACC
performs quality assurance for all genotyping data. All
sites submit phenotypic data to dbGAP at the same
time they submit DNA samples for genotyping to allow
adequate time for data cleaning prior to the genotyping
results being available. The ACC has ensured common
definitions and coding for phenotype variables being
deposited in dbGAP. As mentioned above, the ACC also
facilitates the QA/QC of these data in collaboration
with the other components of the network. This ensures
that accurate genotype and phenotype data will be
deposited to dbGaP.
Another example of early cross-site integration is a
study being performed by the ACC comparing prevalent
ICD-9 codes across network sites for similar and differ-
ent phenotypes to assess the comparability of large
populations taken from different institutions (Figure 2).
The goal of this research is to develop a metric to quan-
tify the similarity and differences of two populations
across all diseases (using the range of ICD-9 codes). In
addition, this method should allow rapid elucidation of
particular differences in the populations. These results
are showing that different institutions employing similar
phenotype definitions produce populations with similar
comorbid disease distributions, while different pheno-
types tend to be more dissimilar.
Table 2 Sample size estimates for GWAS of diabetic
retinopathy with power estimates for the individual sites
and with combined data
eMERGE site Estimated number of
diabetic retinopathy cases
and controls
Power for GWAS, p <
10
-8, MAF = .10 OR =
2.5
Marshfield 367/569 .424
Northwestern 150/1262 .243
Mayo 83/3412 .101
Group Health 324/667 .449
Vanderbilt 260/500 .270
Combined 1184/6410 .999
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Page 7 of 11Choice of cross-network phenotypes
A ranking exercise was developed for network-wide phe-
notypes and completed by all five sites. Elements of the
ranking included the importance of the scientific question,
w h e t h e rG W A Sh a db e e np e r f o r m e df o rt h a to u t c o m e
before, and the relative ease or difficulty of developing
accurate electronic phenotyping algorithms appropriate to
EMR-derived clinical data. Autoimmune hypothyroidism
was the first cross-network phenotype selected to meet
these criteria with sufficient numbers of cases and controls
across the network. However, an examination of records
associated with samples already targeted for GWAS identi-
fied several thousand subjects with hypothyroidism.
This finding further reinforces the potential that generat-
ing dense genomic information across subjects with EMRs
will represent an important and reusable resource for dis-
covery and validation in genome science
Goals for network collaboration
After network sites were selected, and initial progress
was made on the site-specific goals, the External Scienti-
fic Panel (ESP) reviewed the program and generated a
set of further goals for the network as a whole. As a
result, work at each network site has been extended to
include cross-site comparisons and sharing of new tools
and approaches. Examples include, in addition to
hypothyroidism mentioned above, other commonly
acquired clinical laboratory values as continuous traits.
For phenotypes already subjected to numerous
GWAS, such as myocardial infarction and type 2 dia-
betes, investigators were encouraged to identify unique
or compelling features that could be added based on the
ability to mine the entire EMR, and/or to focus on min-
ority subjects, if available. Vanderbilt and Northwestern
partnered to include a large sample of African Ameri-
cans in a study of type 2 diabetes.
Each site has been encouraged to address issues of
non-genetic, environmental exposures and their impact
on specific phenotypes (e.g. baseline socio-economic sta-
tus, smoking) and determine to what degree these mea-
sures can be extrapolated from the EMR. Validation of
the accuracy of smoking data from EMRs is being
undertaken at Vanderbilt, Mayo Clinic and Marshfield
and Marshfield has added smoking history to the vitals
section of their internally-developed EMR.
The ESP indicated that feedback to the EMR commu-
nity is essential, both to private companies that produce
widely-used EMR software and others working on
EMRs. This is especially true for important phenotypes
that can be broadly defined, as that will make it easier
to extend the methods developed to many more sites.
Marshfield will be working to implement eMERGE
recommendations in their internally developed EMR.
Vanderbilt is adding a pediatric component to their
biobank and will examine and report on consent and
proxy issues and share lessons learned with the network.
Phenotyping efforts will be expanded to include drug
responses and their relationship to genome variation.
Drug responses are also likely to be important in defin-
ing other eMERGE-related disease phenotypes (such as
steroid use and its relationship to conditions such as
cataract sub-type and asthma response).
All sites have developed a list of best practices to be
shared with the network and the wider research com-
munity (Table 3).
Summary
Lessons learned
Many challenges have been identified and some have been
overcome, providing a set of information that can be used
by groups wanting to undertake similar research. The big-
g e s tl e s s o n sl e a r n e dt od a t eh a v ec o m ef r o mt h ei n f o r -
matics arena. With the major task to develop validated
algorithms to define phenotype from EMRs, investigators
quickly confirmed that diagnostic codes are insufficient on
their own for research-quality case and control classifica-
tion. Each EMR is unique and EMR systems do not neces-
sarily contain all data elements necessary for a given case
definition. Differences in site populations suggest that the
cohorts selected may not be clinically comparable for
Figure 2 Comparison of ICD9 Codes Between two sites for
patients with Type 2 Diabetes. The graphic shows the prevalence
of ICD-9 codes, grouped into ICD-9 code sections (n=120). The
linear regression line drawn between these two populations show
that these two groups are similar, with a slope slightly favoring a
higher prevalence of more codes at Northwestern (NU) than
Vanderbilt (VU).
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Page 8 of 11some conditions being studied. This is currently being
evaluated by measuring the distribution of disease codes
that co-occur with the primary disease phenotype that is
the focus of a particular GWAS (for example, the fre-
quency of heart disease, stroke and renal failure disease
codes in cohorts selected because the individuals have dia-
betes). Furthermore, if the health system with the biobank
is not the primary health care provider, information neces-
sary to assign case and control status may be lacking
because of care received elsewhere that is not documented
in the EMR. Analysis of free text can be very difficult for
electronic data extraction, but has been shown to be
essential for case/control classification for several of the
phenotypes. A useful strategy is to engage content experts
early in algorithm development. A common validation
methodology to determine the predictive value of the
computerized cohort selection algorithms needs to be
employed. Not surprisingly, achieving the required con-
sensus on data standards and data dictionaries is time con-
suming but essential to the analysis of pooled data from
heterogeneous systems. Data sharing is facilitated where
common or similar institutional policies and procedures
are developed.
Ethical issues that have been identified include
whether the original consent allowed for sharing of data
with dbGaP or investigators from other institutions, and
whether the original consent allowed for the study of
more than one phenotype. Investigators at Group Health
and the University of Washington undertook a sub-
study of reconsent of their subjects to deposit deidenti-
fied research data in dbGaP [24,25].
Potential and real benefits of the network have been
identified. The power of the network includes collabora-
tions with other experts in the field, sharing of proto-
cols, data/drug mining lessons learned that can be
implemented in other EMRs, and the development of
well validated electronic phenotyping algorithms that
can be used for case/control classification and for identi-
fication of potential subjects for study/trial recruitment.
Next steps in Current Funding Cycle
In addition to the outcomes already mentioned, the
eMERGE network is developing and disseminating best
practices recommendations in the areas of electronic
phenotyping and community consultation related to bio-
banking and data sharing. The wealth of phenotypic
information in the EMRs is being mined for additional
GWAS outcomes in the genotyped subjects.
Future Directions for the Network
Plans are underway to expand the network in diversity
of populations and incorporation of GWAS findings
into clinical care.
Summary
The eMERGE network is advancing our knowledge of
best practices related to the linking of biobanks with data
from electronic medical records to facilitate genomic dis-
coveries in an efficient manner. As biobanks are devel-
oped within health care settings, the lessons learned from
the eMERGE network can be applied to these settings to
further scientific discoveries in a timely fashion.
Table 3 Best practices being developed by the eMERGE sites
eMERGE site Best practices
Marshfield Enhance internal EMRs to capture data in a structured format. This may involve changing existing input points in the
record. Information validated against questionnaire data where applicable; Develop and evaluate a computer-based
consenting process along with revisions to the current written informed consent document for our general biobank;
Development of validated electronic algorithms for cataract, HDL, and diabetic retinopathy
Mayo Clinic Manual abstraction vs. EMR-based algorithms: virtually all algorithms ultimately are dependent upon unstructured data;
develop criteria for standardizing data dictionaries and best practices for handling missing data elements; community
engagement survey instrument & educational video to educate community regarding biobank and community
engagement processes; develop institutional policy and procedure for sharing of GWAS data; assess phenotyping
heterogeneity from the EMR
Northwestern Informatics: Identify shortcomings of data capture from routine clinical care and repurposed for research; Develop and
implement common standards for formatting and sharing data; Community engagement: Develop model consent
language; Summarize community engagement efforts around data sharing in our population; Genomics: Develop
process for GWAS data certification review and approval; Other/general: Develop best practices for interacting with
IRBs around biorepository formation and ongoing consultation
Group Health Mapping the electronic derived cases vs. ‘research quality’ (e.g. dementia). How to handle cases from different sources;
Use of “low tech” methods to extract NLP information; identify participant-centered best practices regarding consent
from existing cohorts; develop recommendations for institutions, investigators re consent, data sharing, other issues
with GWAS and related research (products from a consensus panel process)
Vanderbilt Identify shortcomings and enhance internal EMRs to capture data in a structured format; develop methods for
assessing/labeling certainty of data shared to public databases; create a description of the various analogs to human
subjects biobanking in a non-human subjects model
Administrative Coordinating
Center
Creation of a library of searchable phenotype algorithms plus associated metadata; creation of educational materials
on genomic data privacy for IRBs and other regulatory decision makers; develop a re-identification risk framework for
biomedical data to be shared to dbGaP
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